Armata Pharmaceuticals, Inc.
ARMP- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000921114
No open-market purchases or sales by Armata Pharmaceuticals, Inc. insiders were filed in the last 90 days; 53 institutions reported holding it in 13F filings for Q2 2026, worth $32.3M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Armata Pharmaceuticals, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 26 | 23 | −3 |
| Shares | 1.30M | 1.23M | −68.7K (−5.3%) |
| Value | $1.61M | $2.06M | +$447.9K (+27.8%) |
New holders (2)
Institutions that held Armata Pharmaceuticals, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Captrust Financial Advisors | 13,548 | $22.6K | 0.00% |
| Simplex Trading, LLC | 200 | $0 | 0.00% |
Sold out (5)
Institutions that held Armata Pharmaceuticals, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Jane Street Group, LLC | 20,024 | $24.8K |
| Goldman Sachs Group Inc | 13,907 | $17.2K |
| Citadel Advisors LLC | 12,162 | $15.1K |
| Susquehanna International Group, LLP | 10,247 | $12.7K |
| U.S. Capital Wealth Advisors, LLC | 4,000 | $4.96K |